BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38565506)

  • 1. [Advance of research on the role of BCL11A in the occurrence and treatment of β-Thalassemia].
    Lyu A; Chen M; Xu L; Huang H
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Apr; 41(4):417-425. PubMed ID: 38565506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment.
    Mahmoud Ahmed NH; Lai MI
    Cardiovasc Hematol Disord Drug Targets; 2023; 22(4):226-236. PubMed ID: 36734897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-30a regulates γ-globin expression in erythoid precursors of intermedia thalassemia through targeting BCL11A.
    Gholampour MA; Asadi M; Naderi M; Azarkeivan A; Soleimani M; Atashi A
    Mol Biol Rep; 2020 May; 47(5):3909-3918. PubMed ID: 32406020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.
    Bauer DE; Orkin SH
    Curr Opin Genet Dev; 2015 Aug; 33():62-70. PubMed ID: 26375765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Featured Article: Modulation of fetal hemoglobin in hereditary persistence of fetal hemoglobin deletion type-2, compared to Sicilian δβ-thalassemia, by BCL11A and SOX6-targeting microRNAs.
    Fornari TA; Lanaro C; Albuquerque DM; Ferreira R; Costa FF
    Exp Biol Med (Maywood); 2017 Feb; 242(3):267-274. PubMed ID: 27591578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
    Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
    Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
    Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.
    Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR
    Gene; 2022 Apr; 820():146289. PubMed ID: 35143940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of the BCL11A polymorphism on the phenotype of patients with beta thalassemia could be affected by the beta globin locus control region and/or the Xmn1-HBG2 genotypic background.
    Neishabury M; Zamani F; Keyhani E; Azarkeivan A; Abedini SS; Eslami MS; Kakroodi ST; Vesiehsari MJ; Najmabadi H
    Blood Cells Mol Dis; 2013 Aug; 51(2):80-4. PubMed ID: 23541515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic modifiers of β-thalassemia and clinical severity as assessed by age at first transfusion.
    Danjou F; Anni F; Perseu L; Satta S; Dessì C; Lai ME; Fortina P; Devoto M; Galanello R
    Haematologica; 2012 Jul; 97(7):989-93. PubMed ID: 22271886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch.
    Liu N; Hargreaves VV; Zhu Q; Kurland JV; Hong J; Kim W; Sher F; Macias-Trevino C; Rogers JM; Kurita R; Nakamura Y; Yuan GC; Bauer DE; Xu J; Bulyk ML; Orkin SH
    Cell; 2018 Apr; 173(2):430-442.e17. PubMed ID: 29606353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β
    Fu B; Liao J; Chen S; Li W; Wang Q; Hu J; Yang F; Hsiao S; Jiang Y; Wang L; Chen F; Zhang Y; Wang X; Li D; Liu M; Wu Y
    Nat Med; 2022 Aug; 28(8):1573-1580. PubMed ID: 35922667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic expression of Hb F in common high Hb F determinants in Thailand: roles of α-thalassemia, 5' δ-globin BCL11A binding region and 3' β-globin enhancer.
    Prakobkaew N; Fucharoen S; Fuchareon G; Siriratmanawong N
    Eur J Haematol; 2014 Jan; 92(1):73-9. PubMed ID: 24112054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Mithramycin on BCL11A Gene Expression and on the Interaction of the BCL11A Transcriptional Complex to γ-Globin Gene Promoter Sequences.
    Finotti A; Gasparello J; Zuccato C; Cosenza LC; Fabbri E; Bianchi N; Gambari R
    Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common fetal hemoglobin variants in Lebanese patients bearing the codon 29 beta gene mutation associated with different thalassemia phenotypes.
    Brancaleoni V; Moukhadder HM; Consonni D; Koussa S; Di Pierro E; Cappellini MD; Taher A
    Ann Hematol; 2019 Apr; 98(4):833-840. PubMed ID: 30506348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.
    Martyn GE; Wienert B; Yang L; Shah M; Norton LJ; Burdach J; Kurita R; Nakamura Y; Pearson RCM; Funnell APW; Quinlan KGR; Crossley M
    Nat Genet; 2018 Apr; 50(4):498-503. PubMed ID: 29610478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-92a-3p-mediated inhibition of BCL11A upregulates γ-globin expression and inhibits oxidative stress and apoptosis in erythroid precursor cells.
    Li H; Lin R; Li H; Ou R; Wang K; Lin J; Li C
    Hematology; 2022 Dec; 27(1):1152-1162. PubMed ID: 36178486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly efficient therapeutic gene editing of human hematopoietic stem cells.
    Wu Y; Zeng J; Roscoe BP; Liu P; Yao Q; Lazzarotto CR; Clement K; Cole MA; Luk K; Baricordi C; Shen AH; Ren C; Esrick EB; Manis JP; Dorfman DM; Williams DA; Biffi A; Brugnara C; Biasco L; Brendel C; Pinello L; Tsai SQ; Wolfe SA; Bauer DE
    Nat Med; 2019 May; 25(5):776-783. PubMed ID: 30911135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
    N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression.
    Huang P; Peslak SA; Lan X; Khandros E; Yano JA; Sharma M; Keller CA; Giardine B; Qin K; Abdulmalik O; Hardison RC; Shi J; Blobel GA
    Blood; 2020 Jun; 135(24):2121-2132. PubMed ID: 32299090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.